# First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

> **NCT02277717** · PHASE1 · COMPLETED · sponsor: **Byondis B.V.** · enrollment: 185 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** SYD985 (trastuzumab vc-seco-DUBA)

## Key facts

- **NCT ID:** NCT02277717
- **Lead sponsor:** Byondis B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2019-01
- **Final completion:** 2019-10
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02277717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02277717, "First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02277717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*